anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Parkinson's disease (PD) is a neurodegenerative disorder characterized by both motor and non-motor symptoms. Motor symptoms of PD include the clinical triad of tremor, rigidity, and bradykinesia, and typically lead to the initial diagnosis. While there is yet no cure for PD, medical and surgical therapies have been developed that effectively target the motor symptoms of PD. Patients with PD who demonstrate significant motor fluctuations and dyskinesia are considered for subthalamic nucleus (STN) deep brain stimulation (DBS) surgery. Therapeutic DBS leads to a reduction in pathological neuronal synchronization seen in PD. While continuous high-frequency stimulation is effective for ameliorating motor symptoms, the investigators hypothesize that different stimulation patterns which are designed to better target excessive synchrony in a patient-tailored manner, may result in more efficient and effective therapy with fewer side effects. This overarching hypothesis is supported by prior foundational preclinical and clinical research. Medtronic has developed proprietary technology that allows implantable neural stimulators (INS) to deliver both standard clinical electrical stimulation therapy and to record bioelectric data (i.e. local field potentials; LFPs) through DBS leads implanted in the brain. Medtronic's 3rd-generation sensing DBS INS, Percept PC, is FDA-approved for treating PD and can be used to explore unique biomarkers of brain state changes associated with activities of daily living and disease symptomatic states.

This research will use Percept PC INS latent capabilities to deliver research stimulation. Importantly, all stimulation in this research project will be delivered using charge-balanced pulses, in compliance with all FDA safety guidelines including frequency (≤ 250 Hz) and charge density (30 µC/cm2/phase). At the conclusion of the research study, standard clinical stimulation will be re-activated.
<P>PROBLEM TO BE SOLVED: To provide a peptide affording different functional expressions from cell killing or apoptosis defense properties by a difference in sites localized in cells and to provide a prophylactic/therapeutic agent, etc., requiring cell killing actions or apoptosis defense actions and comprising the peptide as an active ingredient.  <P>SOLUTION: The peptide composed of 17 amino acid at the N-terminus of an neuronal EAAC1 [a neuronal glutamate transporter (neuronal excitatory amino acid carrier 1)] binds to an HCCS (holocytochrome C synthase). When the N-terminal peptide of the EAAC1 is introduced into mitochondria, the peptide specifically binds to the HCCS to inhibit the HCCS activity. Thereby, a respiratory chain is cleaved to provide the cell killing properties. When the N-terminal peptide of the EAAC1 is localized in the cytoplasm, the peptide binds to the HCCS in the cytoplasm to reduce the free HCCS. As a result, an XIAP (an apoptosis inhibitory protein family which is an inhibitory factor of caspase) consumed by the HCCS is difficult to consume. Thereby, the apoptosis defense properties through the caspase are provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Epilepsies are a group of neurological disorders characterized by abnormal spontaneous brain activity, involving multiscale changes in brain functional organizations. However, it is not clear to what extent the epilepsy-related perturbations of spontaneous brain activity affect macroscale intrinsic dynamics and microcircuit organizations, that supports their pathological relevance. We collect a sample of patients with temporal lobe epilepsy (TLE) and genetic generalized epilepsy with tonic-clonic seizure (GTCS), as well as healthy controls. We extract massive temporal features of fMRI BOLD time-series to characterize macroscale intrinsic dynamics, and simulate microcircuit neuronal dynamics used a large-scale biological model. Here we show whether macroscale intrinsic dynamics and microcircuit dysfunction are differed in epilepsies, and how these changes are linked. Differences in macroscale gradient of time-series features are prominent in the primary network and default mode network in TLE and GTCS. Biophysical simulations indicate reduced recurrent connection within somatomotor microcircuits in both subtypes, and even more reduced in GTCS. We further demonstrate strong spatial correlations between differences in the gradient of macroscale intrinsic dynamics and microcircuit dysfunction in epilepsies. These results emphasize the impact of abnormal neuronal activity on primary network and high-order networks, suggesting a systematic abnormality of brain hierarchical organization.
Promising therapies for chronic low back pain such as yoga need to be studied because conventional treatments such as medication, physical therapy, and surgery frequently do not provide lasting relief. We will use a standardized yoga protocol, developed specifically for this trial by a consensus panel of yoga experts, in a pilot randomized controlled trial for subjects with chronic low back pain. We will recruit 30 predominantly English-speaking minority adults from Boston Medical Center (BMC) and its affiliated clinics with low back pain lasting \>12 weeks and an average pain level in the previous week of 4 or more on a scale of 0 to 10 (0 = no pain, 10 = worst possible pain). Subjects will be randomized to a yoga class once per week for 12 weeks (Group 1) or a wait-list control group (Group 2). All subjects will receive their usual medical care and an educational booklet designed for low back pain patients. Primary outcomes are 12 week pain intensity and functional status measured by the Roland Morris Disability scale. Secondary outcomes include analgesic use, health-related quality of life (SF-36), global improvement, subject satisfaction, adverse events, compliance, work status, and health expenditures. Group 2 will be offered yoga classes at 26 weeks. To refine estimates of effect size and further confirm safety of the protocol, we will also collect data from Group 2 during their yoga classes. This pilot will provide preliminary feasibility and efficacy data to plan a future adequately powered randomized controlled trial of yoga for chronic low back pain in predominantly minority subjects.
PROBLEM TO BE SOLVED: To prepare a composition for a lip capable of allowing a parson to effectively stop smoking or cut down on smoking only by coating the composition on the lip without accompanying unpleasant feeling by including one or not less than two of plant extracts selected from extracts of gardenia, persimmon and pine. SOLUTION: (A) One or not less than two of plant extracts selected from extracts of gardenia, persimmon and pine is obtained by heating and refluxing one or not less than two of Gardenia jasminoides Ellis. forma grandiflora Makino, Diospyros kaki Thunb. and a plant belonging to Pinus with a solvent (e.g. ethanol), filtering the resultant mixture and, if necessary, concentrating the filtrate. The objective composition for a lip having a form of a rouge, a lipstick, etc., is obtained by formulating 0.01-10wt.% component A in terms of an extracted fraction having 100wt.% concentration (i.e., a dried product), (B) optionally 0.001-10wt.% L-ascorbic acid (derivative), oil components, a powder, a humectant, water, a surfactant, a disperser, a antiseptic agent, a flavor, a medicine, a thickener, a lower alcohol, etc.
Nelfilcon A printed contact lens randomly assigned to one eye, with etafilcon A printed contact lens assigned to the fellow eye for contralateral wear. Lenses will be worn for 20 minutes.
PRCIS: While glaucoma is a leading cause of irreversible vision loss, it presents technical challenges in the design and implementation of screening. New technologies such as PRS and AI offer potential improvements in our ability to identify people at high risk of sight loss from glaucoma and may improve the viability of screening for this important disease.
PURPOSE: To review the current evidence and concepts around screening for glaucoma.
METHODS/RESULTS: A group of glaucoma-focused clinician scientists drew on knowledge and experience around glaucoma, its etiology, and the options for screening. Glaucoma is a chronic progressive optic neuropathy affecting around 76 million individuals worldwide and is the leading cause of irreversible blindness globally. Early stages of the disease are asymptomatic meaning a substantial proportion of cases remain undiagnosed. Early detection and timely intervention reduce the risk of glaucoma-related visual morbidity. However, imperfect tests and a relatively low prevalence currently limit the viability of population-based screening approaches. The diagnostic yield of opportunistic screening strategies, relying on the identification of disease during unrelated health care encounters, such as cataract clinics and diabetic retinopathy screening programs, focusing on older people and/or those with a family history, are hindered by a large number of false-positive and false-negative results. Polygenic risk scores (PRS) offer personalized risk assessment for adult-onset glaucoma. In addition, artificial intelligence (AI) algorithms have shown impressive performance, comparable to expert humans, in discriminating between potentially glaucomatous and non-glaucomatous eyes. These emerging technologies may offer a meaningful improvement in diagnostic yield in glaucoma screening.
CONCLUSIONS: While glaucoma is a leading cause of irreversible vision loss, it presents technical challenges in the design and implementation of screening. New technologies such as PRS and AI offer potential improvements in our ability to identify people at high risk of sight loss from glaucoma and may improve the viability of screening for this important disease.
In this study, carrilizumab combined with suvantinib in the second-line treatment of patients with advanced or metastatic cholangiocarcinoma with single arm, open, Exploratory clinical trials. The study plan enlists 60 patients with unresectable or recurrent disease confirmed by histopathology or cytology Or metastatic cholangiocarcinoma (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, distal cholangiocarcinoma). Past acceptance of standard containing Systematic internal medicine anti-tumor therapy with gemcitabine regimen met the inclusion criteria of this study, and carrilizumab combined with cord was given Vantinib oral therapy. The specific treatment regimen was carrilizumab 200mg Q3W d1; Solventinib: 300mg, Orally, once a day, continuously. Treatment continues or until disease progression occurs or the patient becomes intolerant to the treatment regimen The efficacy was evaluated every 2 cycles. The main evaluation of carrilizumab combined with suvantinib in second-line treatment was advanced or Progression-free survival (PFS) in patients with metastatic cholangiocarcinoma.
The existence of many background blood cells hinders the accurate identification of circulating tumor cells (CTCs) in the blood of cancer patients. To unlock this limitation, a hydrodynamic sorting-mechanotyping cytometry (HSMC) integrated with a sorting-concentration chip and a detection chip is proposed for simultaneously achieving the high-throughput cell sorting and the multi-parameter mechanotyping of the sorted tumor cells. The HSMC adopts the spiral inertial microfluidics for label-free sorting of cells in a high-throughput manner, allowing the efficient enrichment of tumor cells from the large background blood cells. Then, the sorted cells are concentrated by the concentration unit and finally passed through the detection unit for hydrodynamic deformation. The HSMC has a high throughput for sorting and detection and can successfully reveal the differences in the cellular mechanical properties. After characterizing and optimizing the single chips, the identification of white blood cells (WBCs) and three types of tumor cells (A549, MCF-7, and MDA-MB-231 cells) is successfully achieved. The identification accuracies for WBCs and different tumor cells are all larger than 94%, while the highest identification accuracy is up to 99.2%. This study envisions that the HSMC will offer an avenue for the analysis of single cell intrinsic mechanics in clinical medicine.
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including peginterferon alfa-2a. Cirrhotic CHC patients coinfected with HIV receiving highly active antiretroviral therapy (HAART) and interferon alfa-2a with or without ribavirin appear to be at increased risk for the development of hepatic decompensation compared to patients not receiving HAART. In Study NR15961 [see Clinical Studies (14.3)], among 129 CHC/HIV cirrhotic patients receiving HAART, 14 (11%) of these patients across all treatment arms developed hepatic decompensation resulting in 6 deaths. All 14 patients were on NRTIs, including stavudine, didanosine, abacavir, zidovudine, and lamivudine. These small numbers of patients do not permit discrimination between specific NRTIs or the associated risk. During treatment, patients' clinical status and hepatic function should be closely monitored for signs and symptoms of hepatic decompensation. Treatment with peginterferon alfa-2a/ ribavirin should be discontinued immediately in patients with hepatic decompensation [see Contraindications (4)].
The invention discloses a reconstruction pill for neurological rehabilitation and a preparation method thereof. The traditional Chinese medicine composition comprises sargentodoxa cuneata, semen vaccariae, roots of whiteflower hogfennel, laminaria japonica, semen litchi, semen raphani, akebia stem, lalang grass thizome, glabrous sarcandra herb and radix glycyrrhizae. The traditional Chinese medicine composition can be prepared into any clinically-acceptable oral pharmaceutical preparation according to the conventional traditional Chinese medicine preparation method. The traditional Chinese medicine composition made of the traditional Chinese medicines has the efficacy of dredging collaterals and recovering hemiplegia, dispelling wind and dredging collaterals, activating blood and eliminating stagnation, depressing qi and resolving phlegm, clearing heat and reducing blood pressure. Clinical curative effect observation verifies that the traditional Chinese medicine composition disclosed by the invention can be used for comprehensively treating apoplexy sequelae such as hemiplegia, facial paralysis, numbness of limbs and the like which are caused by apoplexy, and the curative effect is accurate, reliable and real. The traditional Chinese medicine composition is non-poisonous and harmless, safe and reliable, has no any side effect after being taken, and is safe in clinical use.
Subjects aged between and including 6 and 12 weeks of age at the time of first vaccination received 3 doses of Pediacel™ vaccine at Months 0, 1 and 2, 2 doses of Prevenar™ vaccine at Months 0 and 2, 2 doses of Menjugate™ vaccine at Months 1 and 2 and a booster dose of Menitorix™ at Month 10. All vaccines were administered intramuscularly. Pediacel™ and Menitorix™ vaccines were administered in the right upper anterolateral thigh and Prevenar™ vaccine in the left upper anterolateral thigh and Menjugate™ vaccine in the left lower anterolateral thigh.
PURPOSE: A method for producing solid dispersed body containing ubidecrenone is provided to prevent environmental pollution by organic solvent and enhance small intestine permeability. CONSTITUTION: A method for preparing solid dispersed body containing ubidecarenone comprises: a step of mixing ubidecarenone, d-α-tocopheryl polyethylene glycol sucinate, sorbitol, lactose and starch or trehalose saccharide in water; and a step of drying the mixture. The mixture is performed at 50-70°C. The drying is freeze-drying. The pharmaceutical composition contains the ubidecarenone-containing solid dispersed body. The pharmaceutical composition is formulated in the chewable tablet.
PROBLEM TO BE SOLVED: To prepare a cataplasm for medical use free from a crosslinking agent, extremely improved in cohesive force of the adhesive layer and causing no skin irritation attributable to the absorption of a remaining part of the crosslinking site of an organic peroxide from the skin even in the case where the part remains in an unreacted state. SOLUTION: An adhesive layer mainly consisting of a (meth)acrylic acid alkyl ester (co)polymer is formed on one side of a supporting body, and the coated supporting body is heated at 90-120 deg.C. The (meth)acrylic acid alkyl ester (co)polymer is produced by (co)polymerizing in the presence of an organic peroxide [e.g. 1,1-bis(t-butylperoxy)-2methylcyclohexanel containing two or more peroxide sites (00-bond) each having a different decomposition temperature in a molecule as a polymerization initiator. The peroxide sites decompose very slowly near room temperature, and accordingly, the thickening of the viscosity of a coating solution, the variation with age regarding the adhesivity properties of the product, etc., hardly occur. Further, the cohesive force can be efficiently increased after application even in the system in which a liquid component is compounded.  Thus, the objective product having low irritation can be produced.
Patients undergo two fractions of low dose orbital EBRT on 2 consecutive days. Patients experiencing stable or progressive disease after 12-16 weeks of EBRT undergo additional low dose orbital EBRT over 10 fractions. Patients experiencing partial response or minimal response 1 year after EBRT also undergo low dose orbital EBRT over 10 fractions.
Participants will receive ruxolitinib at their assigned dose taken orally twice daily on a 28-day cycle combined with nivolumab 480 mg IV administered every 4 weeks (i.e. on Day 1 of a 28-day cycle) until disease progression, unacceptable toxicity, or for a maximum of 2 years.
<P>PROBLEM TO BE SOLVED: To precisely specify medical images at the same slice position.  <P>SOLUTION: A slice position deciding section 22 decides a slice position currently shown relating to a first tomographic image as an objective slice position. A first information obtaining section 23 obtains first information J1 from the first tomographic image or by the input of a user. A second information obtaining section 24 obtains a word to be extracted corresponding to the first information J1 from an image reading report RPT as second information J2 and decides an image related to the image reading report RPT obtaining the second information J2 as an image G2 in a corresponding slice position corresponding to the objective slice position. A display screen generating section 26 generates a display screen SC including the image G1 at the objective slice position and the image G2 at the corresponding slice position and displays the same.  <P>COPYRIGHT: (C)2011,JPO&INPIT
The prevalence of type 2 DM and related-complications continues to increase. Diet is a significant factor in the aetiology of type 2 DM. Intakes of zinc and omega 3 fatty acids may modulate glycaemic control, lipid metabolism, and inflammatory processes in the disease. Zinc is involved in many biological processes that include enzyme action, stabilisation of cell membranes, regulation of gene expression, and cell signalling. Zinc supplementation has been demonstrated to improve glycaemic control in both animals and humans. The normalising effect of zinc on glucose homeostasis may relate to its involvement in insulin metabolism. Zinc functions in the synthesis, storage, secretion, and action of insulin. Omega-3 also enhances glycaemic control and dietary supplementation with omega-3 polyunsaturated fatty acids has been shown to improve insulin sensitivity in subjects with DM. Both zinc and omega-3 function to mediate lipid metabolism. Zinc supplementation has been found to be associated with a beneficial increase in HDL cholesterol concentrations in individuals with type 2 DM. The mechanism may again involve insulin, which has been proposed as an independent predictor of plasma HDL. Omega-3 directly activates transcription factors that regulate lipid metabolism and is known to decrease serum triglyceride levels in DM. Zinc appears to beneficially impact oxidative stress-related parameters in DM via a range of mechanisms, including the regulation of copper,zinc superoxide dismutase, metallothionein, NF-κB and nitric oxide signaling. The purpose of this pilot study is to explore the effect of zinc and omega 3 supplementation on hyperglycaemia, dyslipidaemia, chronic inflammation, and oxidative stress in a population with type 2 DM.

This study will recruit 48 postmenopausal women with type 2 DM. Participants will be randomly allocated to one of 4 groups for a period of 12 weeks: placebo, zinc, omega 3, or zinc + omega 3 supplementation. Usual dietary intake will be assessed before and after the trial period using 2-day estimated food records, which will be checked by a research dietitian. Blood samples will be collected from all participants at the start of the intervention (week 0) then at 4 weekly intervals (weeks 4, 8, 12) by qualified phlebotomists. Blood samples will be analysed for plasma zinc, plasma lipids and fatty acids, markers of inflammation and oxidative stress, and indicators of glycaemic control. An aliquot of blood will also be used for the measurement of zinc transporter mRNA levels utilising real-time quantitative PCR techniques.
The invention relates to pharmaceutical compositions from Usnea barbata and their use in the treatment of skin diseases. A preferred composition is the combination with an extract from Hypericum perforatum. The extracts are obtained by hypercritical high-pressure extraction with natural carbonic acid.  A preferred method of production is the common homogenization of 6 % by weight of an extract from Usnea barbata, containing 96 % usnic acid, and 40 % by weight of an extract from Hypericum perforatum, containing 39 % hyperforin.  The pharmaceutical composition brings about an exponentiation of the anti-inflammatory and antimicrobial effects of the extracts and stabilizes the hyperforin. The combination is suitable for external and internal treatment of various skin diseases, especially various forms of dermatitis, and skin aging, and for the treatment of skin infections with Pityrosporon yeast fungi, acne and rosacea.
The counting condition will include the same physical component as the salaat condition. This will include 4 cycles of movement through the four different positions (i.e., standing, bowing at a 90-degree angle with both hands covering the knees, standing again briefly with arms at the sides, prostrating with forehead, hands, knees, and feet touching the ground, followed by sitting with knees bent under the torso, prostrating, and a final sitting position in cycles two and four. The counting condition will include replacing Qur'anic recitation and subsequent supplications throughout the prayer by counting "one one-thousand, two one-thousand, three one-thousand, etc." throughout the duration of time typically required to perform the full salaat.